ERDOSTEINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C8H11NO4S2
Molecular Weight	249.307
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CSCC(=O)NC1CCSC1=O

InChI

InChIKey=QGFORSXNKQLDNO-UHFFFAOYSA-N

InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula	C8H11NO4S2
Molecular Weight	249.307
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.erdosteine.net/
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/18046899, https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf

Erdosteine is an antioxidant compound developed by Edmond Pharma and approved in Europe for the treatment of chronic bronchitis and COPD. Erdosteine has two thiol groups and is believed to act as a free radicals scavenger (through the formation of the active metabolite I, N-thiodiglycolylhomocysteine). Also the drug effect may be due to the inhibition of the activity of elastase enzyme and its interaction with mucosa. The drug got Orphan Drug designation by FDA for the treatment of bronchiectasis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
mucus secretion 6 Target ID: GO:0070254 Sources: https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf	Modulator 817
Neutrophil elastase 4 Target ID: P08246 Gene ID: 1991.0 Gene Symbol: ELANE Target Organism: Homo sapiens (Human) Sources: https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf	Inhibitor 8146
reactive oxygen species biosynthetic process 35 Target ID: GO:1903409 Sources: https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf	Antagonist 2737

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic bronchitis 49 Sources: https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf	Primary		Approved 8307	ERDOTIN Approved Use Mucolytic agent in acute and chronic respiratory diseases.
Chronic obstructive pulmonary disease 171 Sources: http://www.erdosteine.net/	Primary		Approved 8307	ERDOTIN Approved Use Mucolytic agent in acute and chronic respiratory diseases.

PubMed

Title	Date	PubMed
Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone.	2001 May-Jun	11306790
The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils.	2002	12512232
The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone.	2002	12224380
Effects on the reactive oxygen species of erdosteine and its metabolite in vitro.	2002	12109043
The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.	2004	15553660
Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344].	2004 Dec 6	15581425
Inhibitory effects of metabolite I of erdosteine on the generation of nitric oxide and peroxynitrite chemiluminescence by human neutrophils.	2004 Jul	15161993
Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats.	2004 Jun 28	15212977
Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats.	2004 Sep 30	15458572
Erdosteine ameliorates PTZ-induced oxidative stress in mice seizure model.	2005 May 30	15862921
Effect of metabolite I of erdosteine on the release of human neutrophil elastase.	2006	16825803
The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of pulmonary cells.	2006 Feb 15	16377052
Erdosteine against acetaminophen induced renal toxicity.	2006 Jul	16532256
Comparison of the effects of erdosteine and N-acetylcysteine on apoptosis regulation in endotoxin-induced acute lung injury.	2006 Jul-Aug	16489578
Future therapeutic treatment of COPD: struggle between oxidants and cytokines.	2007	18229560
Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease.	2007 Dec	20477170
Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children.	2007 Jan	17256446
Erdosteine treatment attenuates oxidative stress and fibrosis in experimental biliary obstruction.	2007 Mar	17216233
The effects of erdosteine, N-acetylcysteine and vitamin E on nicotine-induced apoptosis of cardiac cells.	2007 May-Jun	17216608
Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.	2007 Sep	18035199
The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats.	2007 Sep 24	17689165
The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.	2008	19281081
Antioxidant effect of sulphurous thermal water on human neutrophil bursts: chemiluminescence evaluation.	2008	17804898
The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of hippocampal neural cells.	2008 Aug 1	18348255
Antioxidant therapeutic advances in COPD.	2008 Dec	19124382
Environmental toxicity, redox signaling and lung inflammation: the role of glutathione.	2009 Feb-Apr	18760298
Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases.	2010 Apr	20616932
Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice.	2010 Aug	20504824
Effects of sulphurous water on human neutrophil elastase release.	2010 Dec	20650977
Association between lung function and exacerbation frequency in patients with COPD.	2010 Dec 9	21191438
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.	2010 Jan 6	20007921
Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide.	2010 Jul-Sep	20616412

Patents

Sample Use Guides

In Vivo Use Guide

1 capsule (300 mg) 2-3 times a day

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 16 19:22:17 UTC 2022` Edited by `admin` on `Fri Dec 16 19:22:17 UTC 2022`
Record UNII	76J0853EKA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ERDOSTEINE

Official Name

English

Erdosteine [WHO-DD]

Common Name

English

ERDOSTEINE [MART.]

Common Name

English

erdosteine [INN]

Common Name

English

ERDOSTEINE [MI]

Common Name

English

(±)-((((TETRAHYDRO-2-OXO-3-THIENYL)CARBAMOYL)METHYL)THIO)ACETIC ACID

Systematic Name

English

MUCOTEC

Brand Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

417413